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Regulatory NK-cell functions in inflammation and autoimmunity
Abstract
Natural killer (NK) cells were viewed traditionally as cytotoxic effector cells whose rapid killing of
infected and transformed cells without preactivation provides a first line of defense prior to the initiation
of an adaptive immune response against infection and tumor development. However, it has become clear
that NK cells interact with various components of the immune system, and therefore have the potential
to function as regulatory cells. While NK cells can assist in dendritic cell (DC) maturation and T-cell
polarization, increasing evidence indicates that NK cells can also prevent and limit adaptive (auto)
immune responses via killing of autologous myeloid and lymphoid cells. Investigating
immunoregulatory NK-cell functions might generate exciting insights into the reciprocal regulation
between NK-cell-mediated innate immunity and adaptive immune responses, improve our capacity to
monitor these cells as surrogate markers for disease activity and treatment responses in autoimmune
diseases, and, perhaps, provide new prospects for NK cell-directed therapies.
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PHENOTYPES AND FUNCTIONS OF NK
CELLS IN HUMANS
Although NK cells were described
originally as a homogenous population
of innate lymphocytes, there is increasing
evidence that NK cells include distinct
subsets with disparate functions, loca-
tions, and developmental origins.
Human NK cells in peripheral blood can
be divided into at least two functional
subsets based on the expression of CD56
and CD16 (Figure 1). CD56dimCD16+ NK
cells constitute about 90% of total blood
NK cells, efficiently kill target cells, and
secrete only low levels of cytokines. In
contrast, CD56brightCD16– NK cells consti-
tute <10% of total blood NK cells, but are
enriched in secondary lymphoid tissues
(1). In contrast to the CD56dimCD16+
NK-cell subset, activated CD56brightCD16–
cells produce many cytokines, including
IFN-γ, TNF, and GM-CSF, but acquire cy-
totoxicity only after prolonged activation
(2). Therefore, cytokine secretion and cy-
totoxic effector functions are separated in
human NK-cell subpopulations.
CD56brightCD16- and CD56dimCD16+
NK cells also differ from each other in
the expression of inhibitory and activat-
ing NK-cell receptors, as well in the ex-
pression of adhesion molecules and
chemokine receptors which facilitate
homing to lymphoid tissues and sites of
inflammation. NK-cell activation during
target cell recognition is controlled by
germ line encoded activating and in-
hibitory receptors on these innate lym-
phocytes. Among these, triggering of
killer immunoglobulin-like receptors
(KIRs) as well as of the CD94/NKG2A
receptor on NK cells by classical and
nonclassical MHC class I molecules de-
livers negative signals that prevent target
cell killing (3). In contrast, engagement
of activating receptors such as CD16
 (FcgRIII), NK cell protein 30 (NKp30),
NKp44, NKp46, DNAM-1, and NKG2D
by antibody opsonization or ligands
whose expression is upregulated follow-
ing infection, transformation, or cellular
stress, provides an NK-cell activating sig-
nal (4,5). Of the above-mentioned in-
hibitory receptors, cytokine-secreting
CD56brightCD16– NK cells express high
levels of the inhibitory CD94/NKG2A
complex recognizing HLA-E, but lack
MHC class Ia allele-specific killer cell Ig-
like receptors, which are, in contrast, ex-
pressed by CD56dimCD16+ NK cells. Both
NK-cell subsets express the activating re-
ceptors NKG2D as well as NKp30 and
NKp46, but expression of the antibody-
dependent cellular cytotoxicity mediat-
ing receptor CD16 (FcgRIII) is confined
to the CD56dimCD16+ subset (6). There-
fore, cytokine secreting CD56brightCD16–
NK cells express a more rudimentary
repertoire of inhibitory NK-cell receptors
than cytotoxic CD56dimCD16+ NK cells.
CD56brightCD16– NK cells constitu-
tively express CD62L (L-selectin) and
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CCR7, which allows their recruitment
from the blood into lymphoid tissues
and sites of inflammation (7,8). In fact,
the CD56brightCD16– subset is markedly
enriched in secondary lymphoid tissues,
constituting up to 75% of NK cells in
lymph nodes and 50% in the spleen (9).
Even so, only 5% of lymph node
mononuclear cells are NK cells, as
lymph nodes are suggested to harbor
40% of all human lymphocytes; whereas
probably only 2% of all lymphocytes cir-
culate through peripheral blood at any
given moment, CD56brightCD16– NK cells
in secondary lymphoid organs constitute
a significant pool of innate effector cells
in humans. It is also noteworthy that the
infiltrating NK cells in a number of
human inflammatory lesions were found
to be mainly CD56brightCD16– NK cells,
although the CD56dimCD16+ subset ex-
presses chemokine receptors that could
also guide them to these sites (10–13).
The homing cells were negative for per-
forin and had an increased capability to
produce IFN-γ upon stimulation with a
combination of IL-12 and IL-18, suggest-
ing a prominent role for CD56brightCD16–
NK cells both in secondary lymphoid
tissues and at sites of infection and
 inflammation.
IMMUNOREGULATORY NK-CELL
FUNCTIONS
Dendritic cells (DCs) are potent
 antigen-presenting cells that initiate and
regulate immune responses. They are po-
tent stimulators of naïve T cells, key in-
ducers of primary immune responses,
and play a central role in the develop-
ment and maintenance of T-cell toler-
ance. NK cells are found in close associa-
tion with DCs in both secondary
lymphoid tissues and at inflammatory
sites (14–17). DCs can activate resting
NK cells directly, by cell-to-cell contact;
and indirectly, via the secretion of cyto -
kines such as type I IFNs, IL-12, IL-15,
and IL-18. Among the soluble factors,
IL-12 has been observed to induce IFN-γ
secretion and proliferation repeatedly,
and was thought to be the most pivotal
signal-enhancing factor for NK-cell effec-
tor functions in humans and in mice
(15,18–21). IL-15 appears to determine
NK cell differentiation and survival,
thereby possibly promoting NK-cell ex-
pansion (15,22,23). In addition, type I
IFNs were suggested primarily to aug-
ment NK-cell cytotoxicity (24), but IL-12
can also contribute to enhancing this
NK-cell function (21). Thus, different DC
cytokines trigger different NK-cell–effector
functions, enabling DC subsets or differ-
ently matured DCs to elicit a spectrum of
NK-cell responses.
After in vivo stimulation with TLR lig-
ands or bacterial and viral infection, it
was shown that myeloid CD11chigh DCs
need to prime NK cells via presentation
of IL-15 to produce IFN-γ and become
cytotoxic against an MHC class I low cell
line expressing NKG2D ligands. In hu-
mans, we have shown recently that IL-15
receptor α colocalizes at the synapse be-
tween DCs and NK cells and contributes
to NK-cell survival (22). While cytokines
play a dominant role in human NK acti-
vation by DCs, IFN-α treatment of DCs
additionally upregulates the NKG2D lig-
ands, which seem to activate resting NK
cells in a cell-contact-dependent manner
(25), suggesting that cell contact might
contribute additionally to NK activation
by human DCs under certain inflamma-
tory conditions.
DC-NK cell interactions are bidirec-
tional. Activated NK cells also can
 mature DCs, via TNF and IFN-γ produc-
tion and additional cell-to-cell contact-
dependent signals (26,27), which pro-
mote priming and expansion of CD8+
T cells (28). On the other hand, activated
NK cells can kill autologous immature
myeloid DCs via NKp30-, NKp46-, and
DNAM-1–mediated recognition (29–31).
Resistance to NK lysis was achieved via
upregulation of MHC class I molecules
upon DC maturation, in particular, up-
regulation of HLA-E (32), suggesting that
NK cells expressing the inhibitory recep-
Figure 1. Human NK cells in peripheral blood can be divided into at least two subsets
based on the expression of CD56 and CD16. The major subset of CD56dimCD16+ NK cells
constitutes ~90% of total blood NK cells, kills target cells upon proper recognition, and se-
cretes only low levels of cytokines. CD56brightCD16– NK cells (<10% of total blood NK cells,
but 75% of NK cells in secondary lymphoid tissues), in contrast, produce many cytokines,
including IFN-γ, TNF, and GM-CSF, upon stimulation by proinflammatory cytokines, but ac-
quire cytotoxicity only after prolonged activation. In addition, both subsets differ from
each other with respect to expression of inhibitory and activating receptors. Although
CD56brightCD16– NK cells express high levels of the inhibitory CD94/NKG2A complex recog-
nizing HLA-E, they do not express MHC class I allele-specific killer cell Ig-like receptors that
are, in contrast, expressed by CD56dimCD16+ NK cells. Moreover, only CD56brightCD16– NK
cells express homing markers for secondary lymphoid organ (SLO), such as CCR7 and
CD62L, and immature lymphocyte markers, such as c-KIT.
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tor for HLA-E recognition, that is,
CD94/NKG2A, are particularly impor-
tant in editing nonimmunogenic DCs. In
addition to DCs, other myeloid cells also
have been found to be susceptible to NK-
cell cytotoxicity. Along these lines, acti-
vated macrophages have been found to
be susceptible to NKG2D-dependent cy-
totoxicity by NK cells (33), and we have
shown recently that human microglial
cells, resident macrophage-like antigen
presenting cells (APCs) of the central
nervous system (CNS), are lysed by acti-
vated NK cells via NKG2D- and NKp46-
mediated recognition (34). Similar to im-
mature DCs, resting microglia are
susceptible to NK-cell–mediated cytotox-
icity while microglial activation and up-
regulation of MHC class I molecules pro-
tected these CNS-resident APCs from
being killed by NK cells (34). We suggest
that this mechanism reduces the pool of
immature DCs and resting microglial
cells during immune activation, but al-
lows fully activated APCs to present
antigens to infiltrating T cells and to ini-
tiate a limited immune response. In con-
trast to DCs and microglia, monocyte-
 derived macro phages are resistant to
autologous NK-cell cytotoxicity, unless
they become activated by high doses of
lipopolysaccharide (LPS), and express
NKG2D ligands (NKG2DL) (33). This in-
dicates that the stimulatory signal result-
ing from NKG2D–NKG2DL interactions
overcomes the inhibitory signal provided
by MHC class I ligands during recogni-
tion of activated macrophages by NK
cells. The latter study also indicates fun-
damental differences between different
subsets of myeloid cells in their suscepti-
bility toward NK-cell–mediated killing.
Although all of the above mentioned
studies were performed in vitro, and defi-
nite evidence that these mechanisms are
also operative in vivo is still lacking, the
results obtained suggest that activated
NK cells might play an important regula-
tory role by selectively editing APCs
during the course of immune responses.
In addition to regulation of myeloid
cells by NK cells, several studies also
have shown the importance of NK cells
for promoting Th1 polarization of CD4+
T cells through production of IFN-γ, a cy-
tokine that not only initiates, but also re-
inforces Th1 differentiation. During ex-
perimental Leishmania major infection,
NK cells are recruited rapidly to lymph
nodes where they are found in close con-
tact to the same DCs as antigen-specific
CD4+ T cells providing the IFN-γ re-
quired for the induction of Th1 polariza-
tion (17). A similar effect was observed in
allogeneic immune responses during
which NK cells produce high levels of
IFN-γ that are sufficient to mediate T-cell
polarization via acting on naïve T cells
directly, and by enhancing DC matura-
tion (35–37). In addition to their function
in T-cell polarization, NK cells express-
ing OX40 ligand and CD86 upon ligation
of the activating FcgRIII (CD16) are capa-
ble of inducing IFN-γ production and
proliferation of autologous T cells (38).
Moreover, a supportive role of NK cells
in B-cell activation and the promotion of
isotype class switching has also been
documented (39–41). These studies indi-
cate that NK cells, particularly the cy-
tokine secreting CD56brightCD16– subset
(37), can influence T-cell polarization
during primary immune responses.
In addition to shaping T-cell responses,
NK cells can, however, also dampen these.
Following T-cell activation, T cells upregu-
late NKG2D ligands and become suscepti-
ble to autologous NK-cell–mediated cell
lysis in vitro (42–44). In this context, Lu et
al. (45) demonstrated that the interaction
between the mouse homologue of the
human MHC class Ib molecule HLA-E,
Qa-1-Qdm, on activated T cells and
CD94/NKG2A inhibitory NK-cell recep-
tors, protects activated CD4+ T cells from
perforin-mediated NK-cell cytotoxicity.
Ab-dependent blockade of this Qa-1-
NKG2A interaction resulted in potent
NK-dependent elimination of activated
autoreactive T cells and amelioration of
experimental autoimmune encephalo -
myelitis (EAE) in myelin oligodendrocyte
glycoprotein (MOG) 35–55 immunized
C57BL/6 mice (45). Thus, NK cells con-
tribute to the resolution of adaptive im-
mune responses via deletion of activated
T cells in vivo. The latter study provided a
mechanistic insight into the finding that
NK-cell depletion profoundly influences
the outcome of T-cell–mediated auto -
immune disease models as outlined below.
NK-CELL FUNCTION IN EXPERIMENTAL
AUTOIMMUNE DISEASES
Because of the lack of mouse strains
that are selectively deficient in NK cells,
the study of NK-cell function in vivo has
been challenging in the past (46). Animal
models of autoimmune diseases provide
evidence for both disease-accelerating
and disease-protective effects of NK cells
(Figure 2). The contradictory results
achieved by NK-cell depletion are best il-
lustrated in EAE, the animal model of
multiple sclerosis (MS). It has been sug-
gested that NK cells could be pathogenic
by shaping Th1- polarized adaptive im-
mune responses and by activating CNS-
infiltrating DCs (47). Indeed, several
mouse strains which have defective NK-
cell functions, such as IL-18 deficient
mice, or that are devoid of NK cells, such
as T-bet deficient mice, are resistant to
EAE induction (48,49). Surprisingly, most
studies in the EAE model reported that
NK cells protect from  autoimmune-
mediated tissue damage, presumably by
editing initiator and effector cell popula-
tions (45,50–52).  Antibody-mediated de-
pletion of NK cells exacerbated EAE
pathology in Lewis rats, SJL mice, and
C57BL/6 mice (50,51,53), whereas adop-
tive transfer of in vitro- generated NK
cells from the bone marrow decreased
the severity of EAE in DA rats (54). Fur-
thermore, it was observed that NK-cell
depletion resulted in increased prolifera-
tion and IFN-γ production of T cells spe-
cific for the antigen that was used to in-
duce EAE (50). Interestingly, opposite
findings were observed in a different
study using the same mouse strain im-
munized with the same myelin antigen
(47). Contradictory findings on the ef-
fects of NK-cell depletion also were re-
ported in animal models of type 1 dia-
betes (T1D). Whereas antibody-mediated
NK-cell depletion was protective in one
study (55), another report suggested that
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NK cells protect from T1D through secre-
tion of perforin, IFN-γ, or immunoregu-
latory cytokines (56,57). Such apparently
controversial findings might be ex-
plained, at least in part, by differences in
the model system used to determine NK-
cell function. For EAE induction, timing
of myelin immunization and NK-cell
 activation/depletion could be critical for
the outcome; NK cells could modulate
and suppress T-cell polarization and ef-
fector function during the initiation of
autoimmune responses against auto -
antigens, but might contribute to im-
munopathology by directly causing tis-
sue damage during progression of the
established disease. In addition, using
different tools and protocols to achieve
NK-cell depletion could explain different
outcomes. Unfortunately, no antibody
targets NK cells specifically. The most
frequently used antibodies for NK-cell
depletion target NK1.1 and asialo-GM1,
which also are expressed on natural
killer T cells (NKT cells) and a subset of
cytotoxic T cells, respectively. Moreover,
 antibody-mediated NK-cell depletion
could be preceded by NK-cell activation
and IFN-γ production, or might preferen-
tially target distinct subsets of NK cells
that mediate divergent effects on EAE
initiation and progression. Studies in
mice which allow selective in vivo abla-
tion of NK cells (46) might be helpful in
better characterizing the functional im-
pact of NK cells on the initiation and
progression of experimental autoimmune
diseases in the future.
NK-CELL (DYS)FUNCTION IN HUMAN
AUTOIMMUNE DISEASES
Several studies reported that individu-
als with autoimmune diseases such as MS
and systemic lupus erythematosus (SLE),
have fewer blood NK cells compared with
healthy subjects. Moreover, NK cells iso-
lated from patients with MS were found
not only to be decreased in frequency, but
also to be impaired in effector function
(58–68). Notably, patients with hemo-
phagocytic lymphohistiocytosis (HLH), a
rare condition characterized by impaired
or absent function of the  perforin/
granzyme system in NK cells and cyto-
toxic T-cells, demonstrated decreased NK-
cell activity. This resulted in increased
T-cell and sustained-macrophage activa-
tion, and in the production of large quan-
tities of the lymphokines IFN-γ, TNF-α,
and GM-CSF, as well as of IL-1 and IL-6
(69). The macro phage activation syn-
drome (MAS), now considered a special
form of HLH, occurs in children and
adults with autoimmune diseases, espe-
cially systemic juvenile rheumatoid arthri-
tis (sJRA) (70). Interestingly, patients with
sJRA show decreased NK-cell frequencies
and impaired NK-cell functions compared
with children with other forms of juvenile
rheumatoid arthritis such as pauciarticu-
lar and polyarticular JRA, even in the ab-
sence of MAS (71,72), which can, how-
ever, be triggered by environmental
insults such as viral infections (73). Thus,
patients with HLH and sJRA represent an
example for an association of NK-cell dys-
function and excessive immune activa-
tion, which could contribute, potentially,
to the initiation and maintenance of auto-
immune responses.
On the other hand, there are many
studies which found no differences in
NK-cell frequencies and functions in pa-
tients with common autoimmune dis-
eases compared with healthy controls
(74–77). These contradictory findings are
difficult to interpret since all of the afore-
mentioned studies differed widely in
their criteria used to classify NK cells.
Some of the older reports did not distin-
guish between NK cells and NKT cells
and none of the above studies differenti-
ated between CD56brightCD16– and
CD56dimCD16+ NK cells. Moreover, the
assays and protocols used to study NK
cell frequencies and functions, as well as
the patient populations studied, varied
significantly (78). With these caveats in
mind, genetic predisposition for autoim-
mune diseases has been linked to NK
cells, and successful therapies of autoim-
mune diseases correlated with changes
in the NK-cell compartment.
The genetic analysis of NK cells has
focused mainly on KIR allele typing.
KIRs are expressed on NK cells and
subsets of T cells. The KIR genes are ex-
tremely polymorphic, probably more
than the HLA loci, and the KIR gene
complex is polygenic with varying
numbers of inhibitory and activating re-
ceptors (79). HLA class I molecules
serve as ligands for the KIR. Interac-
tions of the independently segregating
KIR and HLA loci are important for rec-
ognition of targets by NK cells. Several
studies correlated incidence and pro-
gression of infectious and autoimmune
diseases with the expression of particu-
Figure 2. Immunoregulatory Functions of NK cells. Depending on the model system, NK
cells were found to either accelerate or inhibit the development of autoimmune diseases.
(A) NK cells could contribute to autoimmune inflammation by shaping Th1-polarized
adaptive immune responses, by activating DCs, and by causing tissue destruction directly.
(B) On the other hand, NK cells could be protective by editing initiator and effector cell
populations such as antigen-presenting cells (APC)—including DCs, macrophages, and
microglia, and autoreactive T cells via their cytotoxicity.
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lar KIRs, as well as with HLA–KIR
combinations. For example, in patients
with psoriasis and psoriatic arthritis,
conditions that have long been associ-
ated with HLA-C, specifically with the
C2 allotype gene HLA-Cw*06, it has
been reported that activating KIR genes
(usually KIR2DS1 and/or KIR2DS2) are
at a higher frequency in patients than in
healthy control individuals (80,81).
These studies suggest that the overall
balance of activating and inhibitory
composite KIR–HLA genotypes con-
tributes to the susceptibility toward au-
toimmune diseases. However, it re-
mains to be defined whether these
genotypes also translate into functional
differences (82).
Stronger evidence for a regulatory role
of NK cells in MS stems from immuno -
monitoring of a phase II therapy trial in
MS. The rationale for the use of a hu-
manized IgG1 monoclonal antibody tar-
geting the interleukin-2 receptor α chain
(daclizumab) in patients with  auto -
immune diseases such as MS was to block
the proliferation of antigen- activated
 autoreactive T cells. Indeed, results of
four open-label studies of intravenous
daclizumab in patients with active forms
of either RRMS or secondary progressive
MS (SPMS) have suggested beneficial
 effects of daclizumab for both add-on
and monotherapy protocols as measured
by magnetic resonance imaging (MRI)
and clinical outcomes (83). Surprisingly,
CD4+ and CD8+ T-cell counts were de-
creased only moderately in patients re-
sponding to therapy. In stark contrast,
CD56brightCD16– NK cells increased in
frequency in the blood of treated patients
and the suppression of disease activity,
as quantified by MRI, correlated with
the expansion of blood NK cells (84).
 Notably, NK cells isolated from patients
during, but not before, therapy killed au-
tologous-activated T cells even without
the need for NK-cell activation in vitro
(84). Similar observations were made in
patients who received the identical
 monoclonal antibody for the treatment of
 auto immune uveitis (85). In addition, pa-
tients with MS receiving IFN-β therapy
also show an increase in the frequency
of CD56brightCD16– NK cells within 3
months of treatment (86). Altogether,
these human studies suggest that NK
cells exert beneficial functions in autoim-
mune diseases. The mechanisms that
could mediate such immunoregulatory
NK-cell functions remain, however,
poorly understood.
Nevertheless, both genetic and im-
munotherapeutic observations point to
an involvement of NK cells in autoim-
mune disease and therefore their role in
these pathologies needs to be better
 understood.
CONCLUSION
NK cells are multicompetent lympho-
cytes with the ability to regulate innate
and adaptive immune responses through
their reciprocal interaction with antigen-
presenting cells as well as T cells and
B cells. Antibody-mediated NK-cell de-
pletion profoundly affects the outcome
of many experimental autoimmune dis-
eases. The observation that NK cells are
decreased in frequency or impaired in
function in patients with autoimmune
diseases are reminiscent of defective
functions noted for regulatory T-cell
populations such as CD4+CD25+ regula-
tory T (Treg) cells and CD1d-restricted
NKT cells, in patients with autoimmune
diseases (87–90).
NK cells include distinct subsets with
disparate repertoires, location, function,
and developmental origin. In analogy to
regulatory T-cell subsets, NK-cell sub-
populations that have yet to be charac-
terized might be particularly important
in regulating autoimmune inflamma-
tion. We suggest that investigating im-
muno regulatory NK-cell functions in
healthy individuals and patients with
autoimmune diseases will generate ex-
citing insights into the reciprocal regula-
tion between NK-cell–mediated innate
immunity and adaptive immune re-
sponses, improve our capacity to moni-
tor these cells as surrogate markers for
disease activity and treatment response,
and, perhaps, provide new prospects for
NK-cell–directed therapies.
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